Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride

Toxicology

Volumn 243, Issue 1-2, 2008, Pages 66-74

  Moura, Flávio José Dutra de ^a   Leal, Pushkin Pires ^a   Furtado, Rogério de Souza ^a   Muniz Junqueira, Maria Imaculada ^a   Veiga, Joel Paulo Russomano ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Antimony pentachloride; Meglumine antimonate; Nephrotoxicity; Pentoxifylline; SbV

Indexed keywords

ANTIMONY; ANTIMONY PENTACHLORIDE; CREATININE; CYTOKINE; MEGLUMINE ANTIMONATE; PENTOXIFYLLINE; SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE PRODUCTION; HISTOPATHOLOGY; INFLAMMATION; KIDNEY CONCENTRATING CAPACITY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM BLOOD LEVEL; SODIUM EXCRETION; URINE OSMOLALITY; URINE VOLUME; WISTAR RAT;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CHLORIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LEISHMANIASIS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 37048999142     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.09.032     Document Type: Article

References (43)

1. Ahasan H.A., Chowdhury M.A., Azhar M.A., Rafiquenddin A.K., and Azad K.A. Deaths in visceral leishmaniasis (Kala-azar) during treatment. Med. J. Malaysia 51 (1996) 29-32
2. Barral-Netto M., Badaro R., Barral A., Almeida R.P., Santos S.A., Badaro F., Pedral-Sampaio D., Carvalho E.M., and Falcoff R. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J. Infect. Dis. 163 (1991) 853-857
3. Baviera A.M., Zanon N.M., Carvalho-Navegantes L.C., Miggliorini R.H., and Kettelhut I.C. Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E702-E708
4. Charlas R., and Benabadji A. Nephrite azotemique au cours du traitement par l'antimoine d'un cas de leishmaniose viscerale infantile. Maroc. Méd. 41 (1962) 1180-1182
5. Chulay J.D., Spencer H.C., and Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am. J. Trop. Med. Hyg. 34 (1985) 702-709
6. Chulay J.D., Fleckenstein L., and Smith D.H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stiboglucanate or meglumine antimoniate. Trans. R. Soc. Trop. Méd. Hyg. 82 (1988) 69-72
7. Coelho, V.N.P.D., 2003. Influência do tratamento, in vitro de fagócitos humanos e murinos com antimoniato de meglumina sobre a fagocitose, produção de radicais de oxigênio e nitrogênio e fator de necrose tumoral-α. Thesis. Universidade de Brasília.
8. Crouch S.P.M., and Fletcher J. Effect of ingested pentoxifylline on neutrophils superoxide anion production. Infect. Immun. 60 (1992) 4504-4509
9. Cuce L.C., Belda-Junior W., and Dias M.C. Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case. Rev. Inst. Med. Trop. São Paulo 32 (1990) 249-251
10. DiPetrillo K., and Gesek F.A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol. 24 (2004) 352-359
11. Doherty G.M., Jensen J.C., Alexander H.R., Buresh C.M., and Norton J.A. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110 (1991) 192-198
12. Donnahoo K.K., Shames B.D., Harken A.H., and Meldrum D.R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J. Urol. 162 (1999) 196-203
13. Gagliardi A.R.T., Veiga J.P.R., Rosa T.T., and Marsden P.D. Pentavalent antimonial inhibition of the osmotic effect of oxytocin on the isolated toad bladder. Brazilian J. Med. Biol. Res. 18 (1985) 567-571
14. Gagliardi, A.R.T., 1986. Efeito inibitório do antimonial pentavalente sobre a ação permeabilizante dos peptídeos neurohipofisários na bexiga isolada do sapo. Thesis. Universidade de Brasília.
15. Gómez-Chiarri M., Ortiz A., Lerma J.L., Lopez -Armada M.J., Mampaso F., Gonzalez E., and Egido J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab. Invest. 70 (1994) 449-454
16. Jolliffe D.S. Nephrotoxicity of pentavalent antimonials. Lancet 9 (1985) 584
17. Kim Y.K., Choi T.R., Kwon C.H., Kim J.H., Woo J.S., and Jung J.S. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren. Fail. 25 (2003) 909-922
18. Kriska M., Kristová V., and Turcáni P. Pentoxifylline-a pharmacodynamically versatile agent. Slovakofarma Revue VIII 2 (1998) 41-47
19. Kocyigit A., Gur S., Gurel M.S., Bulut V., and Ulukanligil M. Antimonial therapy induces circulating proinflamatory cytokines in patients with cutaneous leishmaniasis. Infect. Immun. 70 (2002) 6589-6591
20. Leonard A., and Gerber G.B. Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Mutat. Res. 366 (1996) 1-8
21. Mandell G.L. Cytokines, phagocytes, and pentoxifylline. J. Cardiovasc. Pharmacol. 25 Suppl. (1995) 20-22
22. Marsden P.D., Sampaio R.N.R., Carvalho E.M., Veiga J.P.R., Costa J.L.M., and Llanos-Cuentas E.A. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am. J. Trop. Med. Hyg. 34 (1985) 710-713
23. Matsumura Y., Uchida S., Rai T., Sasaki S., and Marumo F. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J. Am. Soc. Nephrol. 8 (1997) 861-867
24. Neuner P., Klosner G., Schauer M., Pourmojib M., Macheiner W., Grunwald C., Knobler R., Schwarz A., Luge T.A., and Schwarz T. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology 83 (1994) 262-267
25. Olliaro P.L., and Bryceson A.D.M. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today 9 (1993) 323-328
26. Ouellette M., Drummelsmith J., and Papadapoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Updat. 7 (2004) 257-266
27. Ramesh G., and Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110 (2002) 835-842
28. Rees P.H., Kager P.A., Keating M.I., and Hockmeyer W.T. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2 (1980) 226-229
29. Rodrigues M.L., Costa R.S., Souza C.S., Foss N.T., and Roselino A.M. Nephrotoxicity attribute to meglumine antimoniate (glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev. Inst. Med. Trop. São Paulo 41 (1999) 3-7
30. ® and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Rev. Soc. Bras. Med. Trop. 33 (2000) 383-388
31. Salomão R., Castelo-Filho A., Medeiros I.M., and Sicolo M.A. Plasma levels of tumor necrosis factor-α in patients with visceral leishmaniasis (Kala-azar). Association with activity of the disease and clinical remission following antimonial therapy. Rev. Inst. Med. Trop. São Paulo 38 (1996) 113-118
32. V/kg/dia,de 12/12 h,por 30 dias na forma cutâneo-mucosa de Leishmaniose. Rev. Soc. Bras. Med. Trop. 30 (1997) 457-463
33. Savic V., Vlahovic P., Diordjevic V., Mitic-Zlakovic M., Ayramovic V., and Stefanovic V. Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol. Biol. (Paris) 50 (2002) 599-607
34. Semmler J., Gebert U., Eisenhut T., Moeller J., Shonharting M.M., Allera A., and Endres S. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78 (1993) 520-525
35. Sinzinger H. Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandins Leukot. Méd. 12 (1983) 217-222
36. Timoshanko J.R., Sedgwick J.D., Holdsworth S.R., and Tipping P.G. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J. Am. Soc. Nephrol. 16 (2005) 1169-1171
37. Tirmenstein M.A., Plews P.I., Walker C.V., Woolery M.D., Wey H.E., and Toraason M.A. Antimony-induced oxidative stress and toxicity in cultured cardiac myocytes. Toxicol. Appl. Pharmacol. 130 (1995) 41-47
38. Tirmenstein M.A., Mathias P.I., Snawder J.E., Wey H.E., and Toraason M. Antimony-induced alterations in thiol homeostasis and adenine nucleotide status in cultured cardiac myocytes. Toxicology 119 (1997) 203-211
39. Veiga J.P.R., Wollf E.R., Sampaio R.N.R., and Marsden P.D. Renal tubular dysfunction in patients with muco-cutaneous leishmaniasis treated with pentavalent antimonials. Lancet 2 (1983) 569
40. Veiga J.P.R., Rosa T.T., Kimachi T., Wolff E.R., Sampaio R.N.R., Gagliardi A.R.T., Junqueira Jr. L.F., Costa J.M.L., and Marsden P.D. Renal function in patients with muco-cutaneous leishmaniasis treated with pentavalent antimonials. Rev. Inst. Med. Trop. São Paulo 27 (1985) 293-302
41. Veiga J.P.R., Khanam R., Rosa T.T., Junqueira Jr. L.F., Brant P.C., Raick A.N., Friedman H., and Marsden P.D. Pentavalent antimonial nephrotoxicity in the rat. Rev. Inst. Med. Trop. São Paulo 32 (1990) 304-309
42. Ward A., and Clissold S.P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34 (1987) 50-97
43. World Health Organization: Leishmaniasis. http://www.who.int/leishmaniasis/disease_epidemiology/en/index.html (assessed in 25/03/2007).